AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2370391 — intervention group
Group type: EXPERIMENTAL
Intervention: Shrimp challenges (double-blind, placebo-controlled)
Number of subjects: 21
Study 2370391 — intervention group
Group type: EXPERIMENTAL
Intervention: Shrimp hypersensitivity
Number of subjects: 21
Study 2370391 — intervention group
Group type: COMPARATOR
Intervention: Shrimp ingestion
Number of subjects: 21
Study 2370391 — intervention group
Group type: EXPERIMENTAL
Intervention: Shrimp challenges
Number of subjects: 21
Study 7010536 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefamandole prophylaxis
Number of subjects: 140
Study 7010536 — intervention group
Group type: COMPARATOR
Intervention: Penicillin/Flucloxacillin prophylaxis
Number of subjects: 140
Study 7010536 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 140
Study 31584516 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 2549
Study 31584516 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower SBP-CoV tertile
Number of subjects: 2549
Study 31584516 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher SBP-CoV
Number of subjects: 2549
Study 31584516 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower SBP-CoV
Number of subjects: 2549
Study 31584516 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean SBP and SBP-CoV interaction
Number of subjects: 2549
Study 28643119 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based aerobic exercise
Number of subjects: 40
Study 28643119 — intervention group
Group type: EXPERIMENTAL
Intervention: Center-based aerobic exercise
Number of subjects: 40
Study 28643119 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 40
Study 26626993 — intervention group
Group type: EXPERIMENTAL
Intervention: lenalidomide
Number of subjects: 94
Study 26626993 — intervention group
Group type: COMPARATOR
Intervention: lenalidomide plus epoetin β
Number of subjects: 94
Study 25574674 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 70 mg + 2800 IU cholecalciferol once per week
Number of subjects: 40
Study 25574674 — intervention group
Group type: COMPARATOR
Intervention: Placebo + 2800 IU cholecalciferol once per week
Number of subjects: 40
Study 22716474 — intervention group
Group type: EXPERIMENTAL
Intervention: NRXN3 SNPs (specifically rs221473 and rs221497)
Number of subjects: 157
Study 22716474 — intervention group
Group type: COMPARATOR
Intervention: NRXN3 CNV
Number of subjects: 157
Study 20401289 — intervention group
Group type: EXPERIMENTAL
Intervention: Daflon (micronized purified flavonoid fraction) 500 mg (6 tablets daily for 4 days, followed by 2 tablets for 3 days)
Number of subjects: 43
Study 20401289 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 43
Study 18270352 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental strategy (n = 475): target tidal volumes of 6 mL/kg of predicted body weight, plateau pressures not exceeding 40 cm H2O, recruitment maneuvers, and higher positive end‐expiratory pressures.
Number of subjects: 983
Study 18270352 — intervention group
Group type: COMPARATOR
Intervention: Control strategy (n = 508): target tidal volumes of 6 mL/kg of predicted body weight, plateau airway pressures not exceeding 30 cm H2O, and conventional levels of positive end‐expiratory pressure.
Number of subjects: 983
Study 18270352 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental strategy (n = 475)
Number of subjects: 983
Study 18270352 — intervention group
Group type: COMPARATOR
Intervention: Control strategy (n = 508)
Number of subjects: 983
Study 15885294 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 IU daily oral vitamin D3
Number of subjects: 5292
Study 15885294 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg calcium
Number of subjects: 5292
Study 15885294 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 800 IU vitamin D3 and 1000 mg calcium
Number of subjects: 5292
Study 15885294 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5292
Study 12641886 — intervention group
Group type: EXPERIMENTAL
Intervention: Videoconferencing
Number of subjects: 145
Study 12641886 — intervention group
Group type: COMPARATOR
Intervention: Traditional outpatient clinic visits
Number of subjects: 145
Study 10974132 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone (2 mg through a metered-dose inhaler with a spacer)
Number of subjects: 100
Study 10974132 — intervention group
Group type: COMPARATOR
Intervention: Oral prednisone (2 mg per kilogram of body weight)
Number of subjects: 100
Study 8669021 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic procedures (including antireflux operations)
Number of subjects: 0
Study 8669021 — intervention group
Group type: EXPERIMENTAL
Intervention: State registry program for advanced procedures
Number of subjects: 0
Study 1505150 — intervention group
Group type: EXPERIMENTAL
Intervention: Sch 37370 (5 mg/kg)
Number of subjects: 10
Study 1505150 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 6088019 — intervention group
Group type: EXPERIMENTAL
Intervention: IV 5‐fluorouracil (5‐FU) + Methyl‐CCNU (MeCCNU) + Adriamycin (ADM, doxorubicin)
Number of subjects: 192
Study 6088019 — intervention group
Group type: EXPERIMENTAL
Intervention: IV 5‐FU +/‐ MeCCNU
Number of subjects: 192
Study 6088019 — intervention group
Group type: COMPARATOR
Intervention: Adriamycin (ADM)
Number of subjects: 192
Study 31704530 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-balloon catheter (Foley's catheter)
Number of subjects: 120
Study 31704530 — intervention group
Group type: COMPARATOR
Intervention: Double-balloon catheter (Cook cervical ripening balloon)
Number of subjects: 120
Study 30058829 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback condition (n = 101)
Number of subjects: 186
Study 30058829 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU; n = 85)
Number of subjects: 186
Study 30058829 — intervention group
Group type: EXPERIMENTAL
Intervention: Not-on-track clients in feedback condition (n = 60)
Number of subjects: 186
Study 27317703 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen concentrate (FCH)
Number of subjects: 519
Study 27317703 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 519
Study 26173548 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-scope POEM
Number of subjects: 100
Study 26173548 — intervention group
Group type: COMPARATOR
Intervention: Single-scope POEM
Number of subjects: 100
Study 22719014 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm group using point‐of‐care rotational thromboelastometry (ROTEM(®))
Number of subjects: 30
Study 22719014 — intervention group
Group type: COMPARATOR
Intervention: Control group with coagulation management at clinicians' discretion
Number of subjects: 30
Study 22719014 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 22719014 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm group
Number of subjects: 30
Study 22719014 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 20444767 — intervention group
Group type: EXPERIMENTAL
Intervention: Doctor's advice (DA)
Number of subjects: 71
Study 20444767 — intervention group
Group type: COMPARATOR
Intervention: Direct referral to a cessation clinic (CC)
Number of subjects: 71
Study 18767591 — intervention group
Group type: EXPERIMENTAL
Intervention: Tendon‐muscle picking therapy
Number of subjects: 112
Study 18767591 — intervention group
Group type: COMPARATOR
Intervention: Electroacupuncture (EA)
Number of subjects: 112
Study 15811059 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP and metronidazole (M, 400 mg tid) for 10 days (T1)
Number of subjects: 44
Study 15811059 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP, weekly professional supragingival plaque removal for 3 months (PC) and placebo (T2)
Number of subjects: 44
Study 15811059 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP, M and PC (T3)
Number of subjects: 44
Study 15811059 — intervention group
Group type: COMPARATOR
Intervention: SRP and placebo (C)
Number of subjects: 44
Study 12395912 — intervention group
Group type: EXPERIMENTAL
Intervention: Acemetacin 60 mg t.i.d.
Number of subjects: 42
Study 12395912 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin 25 mg t.i.d.
Number of subjects: 42
Study 10768739 — intervention group
Group type: EXPERIMENTAL
Intervention: Motion-sensitized MR-signal
Number of subjects: 20
Study 10768739 — intervention group
Group type: EXPERIMENTAL
Intervention: Motion-compensated MR-signal
Number of subjects: 20
Study 7560468 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized adrenaline (2 mg over 10 min)
Number of subjects: 22
Study 7560468 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized salbutamol (5 mg over 10 min)
Number of subjects: 22
Study 2026133 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (n = 26) used the NLS‐1 system with videodisc instructional programs, prompts, commitments, and feedback.
Number of subjects: 49
Study 2026133 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 23) used the NLS‐1 to enter food purchases only.
Number of subjects: 49
Study 6853746 — intervention group
Group type: EXPERIMENTAL
Intervention: fenoterol hydrobromide (0.5, 1.25, and 2.5 mg)
Number of subjects: 24
Study 6853746 — intervention group
Group type: COMPARATOR
Intervention: isoproterenol (2.8 mg) with phenylephrine (1.25 mg)
Number of subjects: 24
Study 6853746 — intervention group
Group type: COMPARATOR
Intervention: isoetharine (5 mg) with phenylephrine (1.25 mg)
Number of subjects: 24
Study 31909470 — intervention group
Group type: EXPERIMENTAL
Intervention: Torasemide
Number of subjects: 40
Study 31909470 — intervention group
Group type: COMPARATOR
Intervention: Furosemide
Number of subjects: 40
Study 30324508 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lignocaine with 1:80,000 adrenaline and 7.4% sodium bicarbonate
Number of subjects: 50
Study 30324508 — intervention group
Group type: COMPARATOR
Intervention: 2% lignocaine with 1:80,000 adrenaline
Number of subjects: 50
Study 27656953 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) training 3 times a week for 8 weeks
Number of subjects: 25
Study 27656953 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-exercising)
Number of subjects: 25
Study 25134740 — intervention group
Group type: EXPERIMENTAL
Intervention: UP4FUN intervention
Number of subjects: 1940
Study 25134740 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1940
Study 21928233 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicarbonate treatment group (Bic)
Number of subjects: 600
Study 21928233 — intervention group
Group type: COMPARATOR
Intervention: Usual-treatment group (no-Bic)
Number of subjects: 600
Study 19397672 — intervention group
Group type: EXPERIMENTAL
Intervention: LED treatment with a 590-nm wavelength LED array
Number of subjects: 20
Study 21040410 — intervention group
Group type: EXPERIMENTAL
Intervention: Telbivudine 600 mg/day for 1 year
Number of subjects: 246
Study 21040410 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine 100 mg/day for 1 year
Number of subjects: 246
Study 16858942 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 58
Study 16858942 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 58
Study 12237663 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (1000 mg/d) and Vitamin E (400 IU/d) supplementation
Number of subjects: 79
Study 12237663 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 12237663 — intervention group
Group type: COMPARATOR
Intervention: Women at low risk (no supplements)
Number of subjects: 79
Study 10522857 — intervention group
Group type: EXPERIMENTAL
Intervention: Gasless laparoscopy
Number of subjects: 17
Study 10522857 — intervention group
Group type: COMPARATOR
Intervention: Conventional CO2 laparoscopy
Number of subjects: 17
Study 7856778 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-level multichannel intervention
Number of subjects: 11
Study 7856778 — intervention group
Group type: COMPARATOR
Intervention: Comparison communities (control)
Number of subjects: 11
Study 1788614 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil (900 mg daily)
Number of subjects: 66
Study 1788614 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenofibrate (300 mg daily)
Number of subjects: 66
Study 7194945 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening meal of 15% of total caloric intake (form A)
Number of subjects: 12
Study 7194945 — intervention group
Group type: COMPARATOR
Intervention: Evening meal of 40% of total caloric intake (form B)
Number of subjects: 12
Study 7194945 — intervention group
Group type: EXPERIMENTAL
Intervention: Both forms A and B
Number of subjects: 12
Study 28000620 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise in polluted urban environment (Street)
Number of subjects: 38
Study 28000620 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise in less polluted environment (Forest)
Number of subjects: 38
Study 25229779 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone-iodine topical antiseptic
Number of subjects: 50
Study 25229779 — intervention group
Group type: EXPERIMENTAL
Intervention: Vapocoolant spray (1,1,1,3,3 pentafluoropropane and 1,1,1,2‐tetrafluoroethane)
Number of subjects: 50
Study 25229779 — intervention group
Group type: COMPARATOR
Intervention: No antiseptic (Group 1)
Number of subjects: 50
Study 22051141 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute rhinosinusitis with allergic rhinitis
Number of subjects: 69
Study 22051141 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute rhinosinusitis
Number of subjects: 69
Study 20144207 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD3778
Number of subjects: 0
Study 20144207 — intervention group
Group type: COMPARATOR
Intervention: loratadine (antihistamine)
Number of subjects: 0
Study 18194848 — intervention group
Group type: EXPERIMENTAL
Intervention: POLI Thr706Ala genotype
Number of subjects: 1089
Study 15938033 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (16 mg/d)
Number of subjects: 28
Study 15938033 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (10 mg/d)
Number of subjects: 28
Study 12736473 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial ACE activity
Number of subjects: 20
Study 10230747 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine (10 mg)
Number of subjects: 159
Study 10230747 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study 8768161 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 60 mg
Number of subjects: 57
Study 8768161 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac 75 mg
Number of subjects: 57
Study 1751798 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-IFN therapy alone
Number of subjects: 0
Study 1751798 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone priming with IFN therapy
Number of subjects: 0
Study 1751798 — intervention group
Group type: COMPARATOR
Intervention: IFN therapy alone
Number of subjects: 0
Study 6109686 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg bd
Number of subjects: 10
Study 6109686 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 200 mg tds and 400 mg at night
Number of subjects: 10
Study 30872130 — intervention group
Group type: EXPERIMENTAL
Intervention: Folate receptor-positive circulating tumour cells (FR+-CTCs)
Number of subjects: 382
Study 30872130 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of FR+-CTC count and maximum tumour diameter (MTD)
Number of subjects: 382
Study 30475845 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-duration DAPT (≤6 months)
Number of subjects: 2216
Study 30475845 — intervention group
Group type: COMPARATOR
Intervention: Standard-duration DAPT (≥12 months)
Number of subjects: 2216
Study 27227460 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) treatment, 3 weekly sessions
Number of subjects: 15
Study 27227460 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 15
Study 24857051 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Roux-en-Y gastric bypass (LRYGB)
Number of subjects: 29
Study 22126102 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Intervention (BI) for illicit drugs (cannabis, cocaine, amphetamine-type stimulants, opioids)
Number of subjects: 731
Study 22126102 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Intervention (BI) for cannabis
Number of subjects: 731
Study 22126102 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Intervention (BI) for stimulants
Number of subjects: 731
Study 22126102 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Intervention (BI) for opioids
Number of subjects: 731
Study 22126102 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control condition
Number of subjects: 731
Study 20392554 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 152
Study 20392554 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study 18397695 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation (133.3 mg lopinavir/33.3 mg ritonavir)
Number of subjects: 72
Study 18397695 — intervention group
Group type: COMPARATOR
Intervention: Reference product (Kaletra 133.3 mg lopinavir/33.3 mg ritonavir)
Number of subjects: 72
Study 15647968 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower molecular weight hyaluronan (LMW HA) - Ostenil
Number of subjects: 43
Study 15647968 — intervention group
Group type: COMPARATOR
Intervention: Higher molecular weight viscosupplement (hylan G‐F 20, Synvisc)
Number of subjects: 43
Study 12486779 — intervention group
Group type: COMPARATOR
Intervention: Local exhaust ventilation (LEV) at 0 cfm
Number of subjects: 0
Study 12486779 — intervention group
Group type: EXPERIMENTAL
Intervention: Local exhaust ventilation (LEV) at 30 cfm
Number of subjects: 0
Study 12486779 — intervention group
Group type: EXPERIMENTAL
Intervention: Local exhaust ventilation (LEV) at 75 cfm
Number of subjects: 0
Study 12486779 — intervention group
Group type: EXPERIMENTAL
Intervention: Local exhaust ventilation (LEV) at low ventilation rate (30 cfm)
Number of subjects: 0
Study 12486779 — intervention group
Group type: EXPERIMENTAL
Intervention: Local exhaust ventilation (LEV) at high ventilation rate (75 cfm)
Number of subjects: 0
Study 9799980 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural anesthesia (CSE)
Number of subjects: 45
Study 9799980 — intervention group
Group type: COMPARATOR
Intervention: Augmented epidural anesthesia (aEA)
Number of subjects: 45
Study 7705106 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized heparin inhalation (1,000 U/kg)
Number of subjects: 13
Study 2677269 — intervention group
Group type: EXPERIMENTAL
Intervention: Empiric care (high-dose antacid therapy: 15-30 ml of high-potency antacid one and three hours after meals and at bedtime)
Number of subjects: 101
Study 2677269 — intervention group
Group type: COMPARATOR
Intervention: Traditional care (upper gastrointestinal radiography as part of initial evaluation)
Number of subjects: 101
Study 2677269 — intervention group
Group type: COMPARATOR
Intervention: Traditional care
Number of subjects: 101
Study 921531 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar sympathectomy
Number of subjects: 51
Study 921531 — intervention group
Group type: COMPARATOR
Intervention: Control (no sympathectomy)
Number of subjects: 51
Study 31931275 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA supplementation
Number of subjects: 48
Study 31931275 — intervention group
Group type: COMPARATOR
Intervention: Control (no DHA supplementation)
Number of subjects: 48
Study 30657120 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 ml/kg of 0.25% caudal bupivacaine mixed with 2 μg/kg neostigmine (group BN)
Number of subjects: 80
Study 30657120 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 ml/kg of 0.25% caudal bupivacaine mixed with 50 mcg/kg midazolam (group BM)
Number of subjects: 80
Study 30657120 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 ml/kg of 0.25% caudal bupivacaine mixed with 0.5 mg/kg ketamine (group BK)
Number of subjects: 80
Study 30657120 — intervention group
Group type: COMPARATOR
Intervention: 1 ml/kg of 0.25% caudal bupivacaine (group B)
Number of subjects: 80
Study 29911776 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-concentration level patch test guided DPCP treatment
Number of subjects: 20
Study 29911776 — intervention group
Group type: COMPARATOR
Intervention: Conventional DPCP treatment
Number of subjects: 20
Study 26123919 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg every 6 months
Number of subjects: 0
Study 26123919 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose study in men
Number of subjects: 0
Study 26123919 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone cycle model
Number of subjects: 0
Study 23473374 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/ml mitomycin C (MMC) applied at the site of discectomy for 5 minutes
Number of subjects: 75
Study 23473374 — intervention group
Group type: COMPARATOR
Intervention: Saline applied at the site of discectomy for 5 minutes
Number of subjects: 75
Study 20456910 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant practice condition (reading aloud sentence stimuli with four Chinese characters)
Number of subjects: 21
Study 20456910 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocked practice condition (reading aloud sentence stimuli with increasing sentence length from two to five characters)
Number of subjects: 21
Study 20456910 — intervention group
Group type: EXPERIMENTAL
Intervention: Random practice condition (reading sentence stimuli of variable length from two to five characters presented in a random fashion)
Number of subjects: 21
Study 19594864 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic group (L. gasseri CECT5714 and L. coryniformis CECT5711)
Number of subjects: 44
Study 19594864 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional yogurt)
Number of subjects: 44
Study 17165052 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Respiratory Muscle Training (RRMT)
Number of subjects: 30
Study 17165052 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance Respiratory Muscle Training (ERMT)
Number of subjects: 30
Study 17165052 — intervention group
Group type: COMPARATOR
Intervention: Placebo Respiratory Muscle Training (PRMT)
Number of subjects: 30